AbbVie Stock News

Blue-chip stocks come to mind. The companies behind these stocks are mature that generate significant profits that they return to shareholders in the form of buybacks and dividends.

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their po...

OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvement from baseline in the Tremor Disability Scale-Revised (TREDS-R) total unilateral score compared to placebo.1 The trial also met all six secondary endpoints.2 Results from safety analyses were generally consistent with the well-established safety profile of onabotulinum...

Geopolitical events, judicial rulings, new law legislation, and policy changes are all circumstances occurring on domestic and international stages that are triggering big stock moves in various industrial sectors.

Drugmaker AbbVie in a regulatory filing on Friday said it expects third-quarter earnings to include a $2.7 billion charge related to in-process research and development (IPR&D) expenses.

St. Louis Financial Planners Asset Management, LLC initiated a new stake in AbbVie (ABBV -0.78%), acquiring 14,630 shares for an estimated $3.39 million in Q3 2025.

AbbVie is outperforming expectations with strong commercial results, pipeline progress, and the legal win that secured Rinvoq's long-term market exclusivity. ABBV has raised the full-year revenue guidance by $1.5 billion since the start of the year, and I am raising my estimate range again to reflect the better-than-expected performance. The pipeline is delivering late-stage wins, notably with ...

AbbVie stock (NYSE: ABBV) rallied 11% in a week, largely driven by a key development that boosted the entire sector: Pfizer's agreement to lower its drug prices for Medicaid and a White House decision to grant a three-year exemption from 100% import tariffs. Since the market sees this event as broadly positive for pharmaceutical companies, ABBV's stock has risen significantly.